Autoantibodies (AABs) neutralizing type I interferons (IFN) underlie about 15% of cases of critical coronavirus disease 2019 (COVID-19) pneumonia. The impact of autoimmunity toward type III IFNs remains unexplored. We included samples from 1,002 patients with COVID-19 (50% with severe disease) and 1,489 SARS-CoV-2-naive individuals. We studied the prevalence and neutralizing capacity of AABs toward IFNλ and IFNα. Luciferase-based immunoprecipitation method was applied using pooled IFNα (subtypes 1, 2, 8, and 21) or pooled IFNλ1–IFNλ3 as antigens, followed by reporter cell-based neutralization assay. In the SARS-CoV-2-naive cohort, IFNλ AABs were more common (8.5%) than those targeting IFNα2 (2.9%) and were related with older age. In the COVID-19 cohort the presence of autoreactivity to IFNλ did not associate with severe disease [odds ratio (OR) 0.84; 95% confidence interval (CI) 0.40–1.73], unlike to IFNα (OR 4.88; 95% CI 2.40–11.06; P < 0.001). Most IFNλ AAB-positive COVID-19 samples (67%) did not neutralize any of the 3 IFNλ subtypes. Pan-IFNλ neutralization occurred in 5 patients (0.50%), who all suffered from severe COVID-19 pneumonia, and 4 of them neutralized IFNα2 in addition to IFNλ. Overall, AABs to type III IFNs are rarely neutralizing, and do not seem to predispose to severe COVID-19 pneumonia on their own.
Get full access to this article
View all access options for this article.
References
1.
AbersMS, RosenLB, DelmonteOM, et al.Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol Cell Biol, 2021; 99(9):917–921; doi: 10.1111/imcb.12495
2.
AbolhassaniH, DelavariS, LandegrenN, et al.Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19. J Allergy Clin Immunol, 2022; 150(5):1059–1073; doi: 10.1016/j.jaci.2022.09.005
3.
AndreakosE, ZanoniI, GalaniIE. Lambda interferons come to light: Dual function cytokines mediating antiviral immunity and damage control. Curr Opin Immunol, 2019; 56:67–75; doi: 10.1016/j.coi.2018.10.007
4.
ArrestierR, BastardP, BelmondoT, et al.Auto-antibodies against type I IFNs in >10% of critically ill COVID-19 patients: A prospective multicentre study. Ann Intensive Care, 2022; 12(1):121; doi: 10.1186/s13613-022-01095-5
5.
AsanoT, BoissonB, OnodiF, et al.X-linked recessive TLR7 deficiency in ∼1% of men under 60 years old with life-threatening COVID-19. Sci Immunol, 2021; 6(62):eabl4348; doi: 10.1126/sciimmunol.abl4348
6.
BastardP, GervaisA, Le VoyerT, et al.Autoantibodies neutralizing type I IFNs are present in ∼4% of uninfected individuals over 70 years old and account for ∼20% of COVID-19 deaths. Sci Immunol, 2021a;6(62):eabl4340; doi: 10.1126/sciimmunol.abl4340
7.
BastardP, OrlovaE, SozaevaL, et al.Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med, 2021b;218(7):e20210554; doi: 10.1084/jem.20210554
8.
BastardP, RosenLB, ZhangQ, et al.Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020; 370(6515); doi: 10.1126/science.abd4585
9.
BastardP, VazquezS, LiuJ, et al.Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunology, 2022a;eabp8966. [Epub ahead of print]; doi: 10.1126/sciimmunol.abp8966
10.
BastardP, ZhangQ, ZhangS-Y, et al.Type I interferons and SARS-CoV-2: From cells to organisms. Curr Opin Immunol, 2022b;74:172–182; doi: 10.1016/j.coi.2022.01.003
11.
BoudewijnsR, ThibautHJ, KapteinSJF, et al.STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected Hamsters. Nat Commun, 2020; 11(1):5838; doi: 10.1038/s41467-020-19684-y
12.
BradfordHF, HaljasmägiL, MenonM, et al.Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets. Cell Rep Med, 2023; 4(1):100894; doi: 10.1016/j.xcrm.2022.100894
13.
BurbeloPD, BrowneSK, SampaioEP, et al.Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood, 2010; 116(23):4848–4858; doi: 10.1182/blood-2010-05-286161
14.
BurbeloPD, CastagnoliR, ShimizuC, et al.Autoantibodies against proteins previously associated with autoimmunity in adult and pediatric patients with COVID-19 and children with MIS-C. Front Immunol, 2022; 13:841126; doi: 10.3389/fimmu.2022.841126
15.
CasanovaJ-L, AbelL. From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell, 2022; 185(17):3086–3103; doi: 10.1016/j.cell.2022.07.004
16.
ChangSE, FengA, MengW, et al.New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun, 2021; 12(1):5417; doi: 10.1038/s41467-021-25509-3
17.
Chauvineau-GrenierA, BastardP, ServajeanA, et al.Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital. J Clin Immunol, 2022; 42(3):459–470; doi: 10.1007/s10875-021-01203-3
18.
CredleJJ, GunnJ, SangkhapreechaP, et al.Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries. Nat Biomed Eng, 2022; 6(8):992–1003; doi: 10.1038/s41551-022-00925-y
19.
EspinosaV, DuttaO, Mc ElrathC, et al.Type III interferon is a critical regulator of innate antifungal immunity. Sci Immunol, 2017; 2(16):eaan5357; doi: 10.1126/sciimmunol.aan5357
20.
EtoS, NukuiY, TsumuraM, et al.Neutralizing type I interferon autoantibodies in Japanese patients with severe COVID-19. J Clin Immunol, 2022; 42(7):1360–1370; doi: 10.1007/s10875-022-01308-3
21.
FekkarA, LamprosA, MayauxJ, et al.Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. Am J Respir Crit Care Med, 2021; 203(3):307–317; doi: 10.1164/rccm.202009-3400OC
22.
FeldJJ, KandelC, BiondiMJ, et al.Peginterferon lambda for the treatment of outpatients with COVID-19: A phase 2, placebo-controlled randomised trial. Lancet Respir Med, 2021; 9(5):498–510; doi: 10.1016/S2213-2600(20)30566-X
23.
FelgenhauerU, SchoenA, GadHH, et al.Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem, 2020; 295(41):13958–13964; doi: 10.1074/jbc.AC120.013788
24.
GalaniI-E, RovinaN, LampropoulouV, et al.Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol, 2021; 22(1):32–40; doi: 10.1038/s41590-020-00840-x
25.
GilbertC, LefeuvreC, PreisserL, et al.Age-related expression of IFN-Λ1 versus IFN-I and beta-defensins in the nasopharynx of SARS-CoV-2-infected individuals. Front Immunol, 2021; 12:750279; doi: 10.3389/fimmu.2021.750279
26.
GoelRR, KotenkoSV, KaplanMJ. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat Rev Rheumatol, 2021; 17(6):349–362; doi: 10.1038/s41584-021-00606-1
27.
GoncalvesD, MezidiM, BastardP, et al.Antibodies against type I interferon: Detection and association with severe clinical outcome in COVID-19 patients. Clin Transl Immunol, 2021; 10(8):e1327; doi: 10.1002/cti2.1327
28.
HadjadjJ, YatimN, BarnabeiL, et al.Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science, 2020; 369(6504):718–724; doi: 10.1126/science.abc6027
29.
HongM, SchwerkJ, LimC, et al.Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med, 2016; 213(12):2539–2552; doi: 10.1084/jem.20160437
30.
JagannathanP, AndrewsJR, BonillaH, et al.Peginterferon lambda-1a for treatment of outpatients with uncomplicated COVID-19: A randomized placebo-controlled trial. Nat Commun, 2021; 12(1):1967; doi: 10.1038/s41467-021-22177-1
31.
JeongSD, LeeH, ChangJY, et al.Increased type III interferons and NK cell functions in SARS-CoV-2-infected children. Signal Transduct Target Ther, 2023; 8:54; doi: 10.1038/s41392-023-01340-8
32.
JõgiP, SoeorgH, IngerainenD, et al.Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study). Vaccine, 2021; 39(38):5376–5384; doi: 10.1016/j.vaccine.2021.07.093
33.
KallasteA, KisandK, AartA, et al.Antibody levels remain high to one-year's follow-up after moderate and severe COVID-19, but not after mild cases. Infect Dis (Lond), 2022; 54(5):345–355; doi: 10.1080/23744235.2021.2018492
34.
KärnerJ, MeagerA, LaanM, et al.Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice. Clin Exp Immunol, 2013; 171(3):263–272; doi: 10.1111/cei.12024
35.
KorolCB, BelkayaS, AlsohimeF, et al.Fulminant viral hepatitis in two siblings with inherited IL-10RB deficiency. J Clin Immunol, 2023; 43(2):406–420; doi: 10.1007/s10875-022-01376-5
36.
KotenkoSV, GallagherG, BaurinVV, et al.IFN-Λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 2003; 4(1):69–77; doi: 10.1038/ni875
37.
LazearHM, SchogginsJW, DiamondMS. Shared and distinct functions of type I and type III interferons. Immunity, 2019; 50(4):907–923; doi: 10.1016/j.immuni.2019.03.025
38.
LevinAT, HanageWP, Owusu-BoaiteyN, et al.Assessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implications. Eur J Epidemiol, 2020; 35(12):1123–1138; doi: 10.1007/s10654-020-00698-1
39.
ManryJ, BastardP, GervaisA, et al.The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies. Res Sq, 2022. [Epub ahead of print]; doi: 10.21203/rs.3.rs-1225906/v1
40.
MathianA, BreillatP, DorghamK, et al.Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. Ann Rheum Dis, 2022; 81(12):1695–1703; doi: 10.1136/ard-2022-222549
41.
MeagerA, VisvalingamK, PetersonP, et al.Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med, 2006; 3(7):e289; doi: 10.1371/journal.pmed.0030289
Prokunina-OlssonL, AlphonseN, DickensonRE, et al.COVID-19 and emerging viral infections: The case for interferon lambda. J Exp Med, 2020; 217(5):e20200653; doi: 10.1084/jem.20200653
44.
Prokunina-OlssonL, MuchmoreB, TangW, et al.A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet, 2013; 45(2):164–171; doi: 10.1038/ng.2521
ReisG, Moreira SilvaEAS, Medeiros SilvaDC, et al.Early treatment with pegylated interferon lambda for Covid-19. N Engl J Med, 2023; 388(6):518–528; doi: 10.1056/NEJMoa2209760
47.
SalumetsA, TserelL, RummAP, et al.Epigenetic quantification of immunosenescent CD8+ TEMRA cells in human blood. Aging Cell, 2022; 21(5):e13607; doi: 10.1111/acel.13607
48.
SanterDM, LiD, GhoshehY, et al.Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. Nat Commun, 2022; 13(1):6992; doi: 10.1038/s41467-022-34709-4
49.
SchogginsJW. Interferon-stimulated genes: What do they all do?. Annu Rev Virol, 2019; 6(1):567–584; doi: 10.1146/annurev-virology-092818-015756
50.
SheppardP, KindsvogelW, XuW, et al.IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 2003; 4(1):63–68; doi: 10.1038/ni873
51.
SmithN, PosséméC, BondetV, et al.Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity. Nat Commun, 2022; 13(1):7254; doi: 10.1038/s41467-022-34895-1
52.
SolanichX, Rigo-BonninR, GumucioV-D, et al.Pre-existing autoantibodies neutralizing high concentrations of type I interferons in almost 10% of COVID-19 patients admitted to intensive care in Barcelona. J Clin Immunol, 2021; 41(8):1733–1744; doi: 10.1007/s10875-021-01136-x
53.
SpositoB, BroggiA, PandolfiL, et al.The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell, 2021; 184(19):4953–4968.e16; doi: 10.1016/j.cell.2021.08.016
54.
StaniferML, KeeC, CorteseM, et al.Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells. Cell Rep, 2020; 32(1):107863; doi: 10.1016/j.celrep.2020.107863
55.
TroyaJ, BastardP, Planas-SerraL, et al.Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J Clin Immunol, 2021; 41(5):914–922; doi: 10.1007/s10875-021-01036-0
56.
TserelL, KoldeR, LimbachM, et al.Age-related profiling of DNA methylation in CD8+ T cells reveals changes in immune response and transcriptional regulator genes. Sci Rep, 2015; 5:13107; doi: 10.1038/srep13107
57.
van der WijstMGP, VazquezSE, HartoularosGC, et al.Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med, 2021; 13(612):eabh2624; doi: 10.1126/scitranslmed.abh2624
58.
VanderheidenA, RalfsP, ChirkovaT, et al.Type I and type III interferons restrict SARS-CoV-2 Infection of human airway epithelial cultures. J Virol, 2020; 94(19):e00985-20; doi: 10.1128/JVI.00985-20
59.
VazquezSE, FerréEM, ScheelDW, et al.Identification of novel, clinically correlated autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide phIP-Seq. Elife, 2020; 9:e55053; doi: 10.7554/eLife.55053
60.
VazquezSE, MannSA, BodanskyA, et al.Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-Seq. Elife, 2022; 11:e78550; doi: 10.7554/eLife.78550
61.
VlachiotisS, AndreakosE. Lambda interferons in immunity and autoimmunity. J Autoimmun, 2019; 104:102319; doi: 10.1016/j.jaut.2019.102319
62.
WangEY, MaoT, KleinJ, et al.Diverse functional autoantibodies in patients with COVID-19. Nature, 2021; 595(7866):283–288; doi: 10.1038/s41586-021-03631-y
63.
World Health Organization. Clinical Management of COVID-19: Living Guideline. World Health Organization: Geneva; 2022
ZhangQ, BastardP, CobatA, et al.Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022; 603(7902):587–598; doi: 10.1038/s41586-022-04447-0
66.
ZhangQ, BastardP, LiuZ, et al.Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020; 370(6515):eabd4570; doi: 10.1126/science.abd4570
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
